The Life Sciences team advised Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH) on its follow-on public offering of 10,810,810 shares of its common stock at $37.00 per share.
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.
The gross proceeds to Deciphera were approximately $400 million. In addition, the company granted the underwriters a 30-day option to purchase up to 1,621,621 additional shares of its common stock.
The Goodwin team was led by partners Richard Hoffman and Sarah Ashfaq and included partners Theresa Kavanaugh, Daniel Karelitz, Ettore Santucci and Edwin O’Connor, associates Isabel Klosterman, Josh Stern and Julia White, and science law clerk Gregory Gutierrez.
For more information, read the press release and articles in Endpoints, FierceBiotech and Seeking Alpha.